1 December 2020 - Merz Therapeutics today announced Health Canada’s notice of compliance for Xeomin (incobotulinumtoxinA) for the treatment of chronic sialorrhea, or excessive drooling, associated with neurological disorders in adult patients. 

Xeomin is the first and only neurotoxin with this licensed indication in Canada.

Xeomin was licensed by Health Canada for adult patients with sialorrhea on the basis of a Phase 3, randomised, double-blind, placebo-controlled, multicenter trial in which 184 patients participated.

Read Merz Pharmaceuticals press release